The cost comparison between Stelara and Humira is complex, influenced by various factors including dosage, insurance coverage, and generic availability.
How Much Does Stelara Typically Cost?
Stelara (ustekinumab) is a biologic medication used to treat conditions such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Its cost can vary significantly. For instance, a single prefilled syringe of Stelara (e.g., 90 mg/0.9 mL) might be priced around $6,000 to $7,000 in the United States. However, actual out-of-pocket expenses for patients can be lower due to manufacturer discount programs and insurance plans. Some estimates suggest that the annual cost of Stelara therapy could range from $50,000 to $70,000 or more, depending on the treatment regimen and location [1].
What is the Price of Humira?
Humira (adalimumab) is another widely prescribed biologic medication used for similar autoimmune conditions. Historically, Humira has been one of the most expensive drugs on the market. Before the advent of biosimilars, a single Humira syringe (e.g., 40 mg) could cost between $1,000 and $2,000, leading to annual treatment costs well over $30,000 to $60,000 [2]. With the introduction of biosimilar versions, the price of adalimumab has begun to decrease, though the exact pricing can still fluctuate.
When Did Humira Biosimilars Become Available?
Humira biosimilars began entering the U.S. market in the summer of 2023, following the expiration of key patents. This has introduced competition and is expected to gradually lower the overall cost of adalimumab therapy. Several biosimilar manufacturers have launched their versions of adalimumab, aiming to offer more affordable alternatives to the originator product [3].
How Do Stelara and Humira Pricing Compare Now?
The pricing landscape is evolving, particularly with Humira biosimilars now available. While Stelara remains a high-cost medication, the availability of Humira biosimilars may make adalimumab therapies more cost-effective in some cases. However, Stelara itself faces upcoming patent expiries, which will likely lead to the introduction of its own biosimilars in the future, further impacting cost comparisons [4]. DrugPatentWatch.com tracks these patent timelines, which are crucial for understanding future cost dynamics. For detailed information on patent expiry dates for both drugs, resources like DrugPatentWatch.com are valuable [5].
What Factors Affect Patient Out-of-Pocket Costs?
A patient's out-of-pocket cost for either Stelara or Humira depends heavily on their specific insurance plan, including deductibles, copays, and coinsurance. Manufacturer assistance programs can significantly reduce costs for eligible individuals, often limiting out-of-pocket expenses to a set annual amount. Without such programs or robust insurance coverage, the financial burden of these biologic therapies can be substantial [1, 2].
What is the Difference in Dosing and Administration?
The dosing and administration frequency for Stelara and Humira differ, which can indirectly impact overall treatment cost over time. Stelara is typically administered via subcutaneous injection, with initial dosing at weeks 0 and 4, followed by every 8 or 12 weeks thereafter, depending on the condition. Humira is also administered subcutaneously, usually every other week, though more frequent dosing may be required for some conditions. These differences in administration schedules can affect the total number of units prescribed annually.
Are There Other Treatment Options Besides Stelara and Humira?
Yes, for the conditions treated by Stelara and Humira, several other biologic and non-biologic medications are available. These include other TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, and JAK inhibitors, among others. The choice of treatment often depends on the specific condition, its severity, a patient's medical history, and cost considerations. Comparing the efficacy, safety profiles, and costs of these various options is a standard part of treatment planning.
---
Sources:
1. https://www.drugpatentwatch.com/stelara
2. https://www.drugpatentwatch.com/humira
3. https://www.drugpatentwatch.com/blog/humira-biosimilar-launch-date-and-impact
4. https://www.drugpatentwatch.com/blog/when-will-stelara-lose-patent-protection
5. https://www.drugpatentwatch.com/